RESTEPS Program to Reduce Stigma and Suicide Risk in Early Psychosis
Tests RESTEPS, an 8-session program, in young people with early psychosis.
Plain-language title generated from the registry record
Registry title: Reducing Stigma - A Treatment for Early Psychosis to Prevent Suicide
Key facts
- Where
- Providence, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 15 and 25 years old?
Source: NCT07898631, who can take part
Where in United States
- Butler HospitalProvidence, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Butler Hospital
- Trial code
- NCT07898631
- Record updated
- 29 October 2026
- Original description
A mental health program, called RESTEPS, will be developed for patients with early psychosis being treated in outpatient mental health centers, focusing on reducing suicide risk by targeting mental health stigma and social support. Youth (n = 35) with psychosis and current/past suicidal thoughts or behaviors will be recruited from community mental health centers to complete an initial open trial examining the feasibility and acceptability of RESTEPS, an 8-session intervention. Participants will be assessed at baseline, mid-intervention, post-intervention, and at a 6-month follow-up.Read full original descriptionShow less
Reducing Stigma - A Treatment for Early Psychosis to Prevent Suicide
A mental health program, called RESTEPS, will be developed for patients with early psychosis being treated in outpatient mental health centers, focusing on reducing suicide risk by targeting mental health stigma and social support. Youth (n = 35) with psychosis and current/past suicidal thoughts or behaviors will be recruited from community mental health centers to complete an initial open trial examining the feasibility and acceptability of RESTEPS, an 8-session intervention. Participants will be assessed at baseline, mid-intervention, post-intervention, and at a 6-month follow-up.
Inclusion: 15-25 years of age; Schizophrenia-spectrum disorder diagnosis (e.g., schizophreniform, schizoaffective disorder, schizophrenia, delusional disorder) or mood disorder with psychotic features (e.g., major depressive disorder with psychotic features, bipolar disorder with psychotic features) confirmed via Structured Clinical Interview for the DSM-5; Positive psychotic symptom duration of < 2 years OR currently receiving treatment in an early psychosis or first-episode psychosis clinic; Suicide risk defined as any lifetime suicide attempt or suicidal ideation (yes to Questions 1, 2, 3, 4, or 5 on the Columbia Suicide Severity Rating Scale or C-SSRS); For participants younger than 18 only, parent/guardian significant other willing to participate in the study; Ability to speak and read English sufficiently to complete study procedures.
Exclusion: Psychotic symptoms due solely to substance intoxication or withdrawal (otherwise, comorbid substance use disorders will be allowed) or a known medical condition; Severe current psychotic symptoms preventing the participant from providing informed consent/assent and/or being able to engage in the study procedures; Involuntary hospital at the time of consent.